Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Corsair Gaming Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Corsair Gaming Inc trades at $8.96 (market cap $968.35M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 4.6× Corsair Gaming Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CRSR | |
|---|---|---|
Market Cap | $4.49B | $968.35M |
Sector | Health | Technology |
52-Week High | $28.06 | $12.14 |
52-Week Low | $20.06 | $4.58 |
Enterprise Value | $3.69B | $1.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Corsair Gaming (CRSR) trades at $8.89, down slightly by 0.11% on the day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly results with Q1 2026 beating expectations but faces profitability challenges with a net margin of just 0.49%. Recent developments include new AI product launches and strategic partnerships, driving positive media coverage and investor optimism about future growth prospects.
The outlook remains cautiously optimistic with analyst consensus pointing to modest upside potential to the $9.00 price target. Key opportunities include expansion into AI hardware and gaming partnerships, while risks center on thin profit margins, competitive pressures, and inconsistent earnings performance. The stock offers speculative growth potential but requires careful monitoring of execution on new initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
